Cellebrite DI Q1 Earnings Call Highlights - MarketBeat

Cellebrite DI Q1 Earnings Call Highlights Written by MarketBeat May 14, 2026 Image from MarketBeat Media, LLC. KEY POINTS Cellebrite said Q1 2026 results met or exceeded the high end of its guidance, with ARR up 21% to $493 million, revenue up 19% to $128.3 million, and adjusted EBITDA up 29% to $30.6 million. The company also posted an 86% gross margin and a 32% trailing 12-month free cash flow margin. The biggest focus was on new AI-driven products, especially Genesis, which management said quickly drew more than 500 registered users across 15+ countries after launch. Cellebrite also moved Guardian Investigate to general availability and highlighted expanding mobile device unlock capabilities. Management said the U.S. federal business is rebounding, helped by FedRAMP High authorization and a 35% year-over-year increase in the federal pipeline. Cellebrite reaffirmed 2026 guidance and expects second-quarter ARR of $510 million to $513 million and revenue growth of 15% to 17%. MarketBeat previews top five stocks to own in June. Cellebrite DI NASDAQ: CLBT reported first-quarter 2026 results that management said met or exceeded the high end of its guidance for annual recurring revenue and adjusted EBITDA, while executives highlighted a wave of new product launches centered on artificial intelligence, cloud-based case management and mobile device access. Chief Executive Officer Tom Hogan said ARR rose 21% year-over-year to $493 million, while adjusted EBITDA increased 29% to $30.6 million. The company’s trailing 12-month free cash flow margin was 32%, and Hogan said Cellebrite’s “rule of x” continued to track above 50. Get Cellebrite DI alerts: SIGN UP Chief Financial Officer David Barter said revenue for the quarter was $128.3 million, up 19% from the prior-year period. Subscription revenue grew 23%, partially offset by an expected decline in non-recurring training, hardware and professional services revenue. Gross profit increased 21% to $110.2 million, representing an 86% gross margin. Barter said first-quarter adjusted EBITDA margin expanded 190 basis points to 23.9%, despite foreign exchange headwinds and a full quarter of costs from Corellium. Cellebrite ended the quarter with $535 million in cash equivalents and investments, essentially unchanged from year-end 2025, primarily because of the acquisition of SCG Canada. AI Products Take Center Stage Much of the call focused on Cellebrite’s new AI offerings, particularly Genesis, which Hogan described as an “agentic next-gen AI solution” designed to deliver rapid insights from complex and disparate digital evidence sources. The company announced Genesis on March 16 and made it available to a select group of early adopters ahead of planned general availability in mid-June. Hogan said Cellebrite expected “one to two dozen takers” for early access, but within eight weeks had more than 500 registered users across more than 15 countries. He said the early-access program had no marketing, pricing or packaging attached. Hogan read several customer comments during the call, including one from a leader of a specialized counterterrorism unit at a regional police force who called Genesis “a quantum leap” in digital evidence analytics. Another customer in Asia Pacific described it as “the finest digital evidence product I have ever used,” citing its ability to process mobile phone data, computers, documents, CCTV and spreadsheets. A detective at a U.S. county sheriff’s office said Genesis identified 16 previously unknown victims in a high-priority online exploitation case within 15 minutes of ingestion, work that otherwise would have required an estimated two weeks of investigator time. Hogan said Cellebrite’s 2026 plan assumed no AI product-specific revenue, but that will “now obviously not be the case.” He estimated the total addressable market for investigative AI over the next four years at roughly $12.5 billion and said AI revenue over that period could approximate the company’s current total revenue if Cellebrite executes well and continues to innovate. In response to an analyst question, Hogan said the company’s assumptions were based in part on an estimated 500,000 detectives and investigators globally and potential spending of $20,000 to $30,000 to improve productivity. He said Cellebrite used more conservative assumptions when considering potential penetration of that market. Guardian Investigate and Unlock Capabilities Expand Portfolio Cellebrite also moved Guardian Investigate into general availability at the end of the first quarter. Hogan described the product as an AI-powered system of record for case management and a modern alternative to a digital evidence management system. He said it is designed to handle digital evidence including video, audio, call records, ballistics, drones, CCTV and mobile phone data. Hogan said Guardian Investigate is meant to help investigative teams build case narratives, collaborate, securely store evidence and analyze data using agentic AI. He said the response from early adopters has been strong and that the company expects steady growth and penetration in the second half of 2026. The company also emphasized progress in device unlocking and access. Hogan said Cellebrite doubled down in the second half of 2025 on Android and iOS unlock capabilities and emerged late in the first quarter with what it believes is “the most advanced and comprehensive platform” for unlocking and accessing a broad range of mobile devices. During the question-and-answer session, Chief Revenue Officer Marcus Jewell said interest in the company’s Advanced Unlock Program has been “incredibly high,” adding that proof-of-concept work is straightforward because customers can connect a phone and see whether it unlocks. Barter said the advanced unlock technology became available in the final 10 days of the quarter and is expected to be a logical attachment in larger platform deals. Federal Business Shows Signs of Rebound Hogan said Cellebrite received FedRAMP High authorization to operate on May 6 after more than two years of investment. He said the authorization, sponsored by the U.S. Department of Justice, allows federal agencies to evaluate and pursue the company’s government cloud offerings, including its Guardian platform. Hogan said the opportunity should ramp gradually over the next several quarters and into 2027 as U.S. federal agencies prioritize technology platforms for fiscal 2027. He also said the U.S. federal business, which was essentially flat in 2025 amid budget pressures and organizational change, is rebounding quickly. According to Hogan, the rebound is being driven by stabilization of agency leadership, anticipated funding for cyber and digital initiatives, appropriations tied to areas such as digital evidence management and advanced analytics, and broader geopolitical instability. He said Cellebrite’s U.S. federal pipeline has increased 35% year-over-year, and the segment’s growth rate is “clearly headed back to the 20s,” with potential to exceed historical mid-20s growth rates based on large strategic initiatives. Barter said the Americas represented 53% of total ARR in the quarter, EMEA represented 35% and Asia Pacific represented 12%. ARR grew 18% in the Americas, 25% in EMEA and 21% in Asia Pacific. He added that growth products, including Guardian, Pathfinder, Corellium and drone forensics, doubled year-over-year. Guidance Reaffirmed for 2026 Barter said Cellebrite’s overall thesis for full-year 2026 is unchanged, and management has increased confidence in the outlook based on the expanded portfolio, platform requests for proposals and pipeline. He said first-quarter growth was expected to be modest because of seasonality and a small base of expiring contracts. For the second quarter, Cellebrite expects: ARR of $510 million to $513 million, implying net new ARR of $17 million to $20 million. Revenue of $130 million to $133 million, representing growth of 15% to 17%. Adjusted EBITDA of $29 million to $31 million, with a margin of 22% to 23%. Barter said the second-quarter outlook includes estimated foreign exchange headwinds of approximately two percentage points, as well as costs related to the company’s expanded C2C user conference and regional launch events. Cellebrite also announced a leadership transition in product and technology. Hogan said Ronen Armon, chief product and technology officer, will retire on July 1. Shiven Ramji has been appointed president of products and technology, effective immediately, and will work with Armon during the transition. Hogan said Ramji brings experience in security, AI and cloud from roles at companies including Auth0, Okta, Amazon and DigitalOcean. Hogan closed by saying he has not been more optimistic about Cellebrite’s future since joining the company in 2023, citing the pace of innovation and the company’s expanded portfolio. Barter said the company remains positioned to re-accelerate ARR growth while maintaining strong operating results and free cash flow. About Cellebrite DI NASDAQ: CLBT Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform. The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com. Should You Invest $1,000 in Cellebrite DI Right Now? Before you consider Cellebrite DI, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list. While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. VIEW THE FIVE STOCKS HERE A GUIDE TO HIGH-SHORT-INTEREST STOCKS MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list. GET THIS FREE REPORT LIKE THIS ARTICLE? SHARE IT WITH A COLLEAGUE. Featured Articles and Offers Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum BY CHRIS MARKOCH | MAY 10, 2026 $30 stock to buy before Starlink goes public (WATCH NOW!) FROM PARADIGM PRESS (AD) Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now BY LEO MILLER | MAY 11, 2026 Before the Moon Base Gets Built, These 4 Companies Win BY THOMAS HUGHES | MAY 11, 2026 The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000 BY JEFFREY NEAL JOHNSON | MAY 12, 2026 The Credit Card Trick That Could Stop the Bleeding FROM FINANCEBUZZ (AD) Navy Catalyst Ignites Odysight’s Growth Engine BY JEFFREY NEAL JOHNSON | MAY 12, 2026 Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? BY RYAN HASSON | MAY 12, 2026 Recent Videos Is This Palantir's Last Great Wealth Opportunity? MARKETBEAT TV | MAY 14, 2026 Watch Video The Last Big Wealth Opportunity Before China Cuts Us Off (3 Stocks to Buy Now) MARKETBEAT TV | MAY 13, 2026 Watch Video If You Own Stocks, Get READY for May 15th MARKETBEAT TV | MAY 12, 2026 Watch Video Stock Lists ALL STOCK LISTS 5GBiotechBlue ChipFAANGGoldLarge CapMarijuanaMicro CapOilREITsRussell 2000Small CapWarren Buffett Investing Tools CALENDARS AND TOOLS Analyst RatingsCryptocurrency ScreenerCongressional TradingDividend IncreasesDividend CalculatorDividend CalendarEarnings AnnouncementsInsider TradesOptions Profit CalculatorPenny StocksPortfolio MonitoringShort InterestStock ComparisonsStock Market HolidaysStock Screener Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. START YOUR 30-DAY TRIAL MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis.